paul collins

MannKind: No Partnership Likely for Inhalable Insulin

If the street had listened to Dr. Bernstein, the former head of the American Diabetes Association, they would have predicted the sudden drop in Mankind's (MNKD) stock last week. Back in December, 2007, Dr. Bernstein predicted that MNKD would fail.

www.ft.com/cms/s/2/94f...

Dr. Bernstein now serves for Generex and has committed his life to developing and obtaining approval for its flagship product, Oral-Lyn. He strongly believes in the safety and efficacy of the product. And, thus I highly doubt that the product will fail. GNBT should see $5/share within the coming year (remember it was $22 just because they had a partnership with Eli Lilly). Now they are in Phase 3 in the USA, and they have regulatory approval in India, one of the largest Diabetes markets in the world. For reference, Dr. Bernstein's bio is below.

Dr. Bernstein, M.D., F.A.C.P. graduated from Dartmouth College and Tufts University School of Medicine. He is board certified in internal medicine (1966) and endocrinology and metabolism (1973). Dr. Bernstein is an associate clinical professor at the Albert Einstein College of Medicine in New York. He is an attending physician at Beth Israel Medical Center, and physician emeritus at Lenox Hill Hospital and Montefiore Medical Center, all in New York. He was formerly Director of the Beth Israel Health Care Systems Diabetes Management Program. Dr. Bernstein was president of the American Diabetes Association in 1998-99 and was for many years a member of the ADA's Board of Directors and its Executive Committee. He received the ADA's Banting Medal for Service in 1999. Dr. Bernstein presently serves on several ADA committees and on the Board of Directors of the American Diabetes Association Research Foundation.